Economic burden and health-related quality of life of herpes zoster disease in rural areas of Jiangsu Province
-
摘要:
目的 分析江苏省农村地区40岁及以上带状疱疹(herpes zoster, HZ)患者的疾病经济负担和健康相关生命质量情况。 方法 对研究地区40岁及以上HZ患者进行前瞻性的随访调查。通过调查问卷获得患者的疾病经济负担以及欧洲五维健康量表(European quality of life-5 dimensions, EQ-5D)的健康效用值和视觉模拟标尺(visual analogue scale, VAS)评分。 结果 共获得310例HZ患者的有效问卷。310例患者直接经济负担、间接经济负担和无形经济负担中位数分别为351.050元、582.900元和2 000.000元。随访初期患者的健康效用值和VAS评分均较低，后期逐渐恢复。 结论 江苏省农村地区HZ疾病经济负担较重，并且疾病降低了患者的健康相关生命质量。 Abstract:Objective To analyze the economic burden and health-related quality of life of patients with herpes zoster (HZ) aged 40 years and over in rural areas of Jiangsu Province. Methods A prospective follow-up survey was carried out among HZ patients at the age of 40 years and above in the study area. The economic burden of disease, health utility value and Visual analogue scale (VAS) score of European quality of life-5 dimensions (EQ-5D) were obtained by questionnaire. Results A total of 310 patients received valid questionnaires. The median direct economic burden, indirect economic burden and intangible economic burden of 310 patients were 351.050 yuan, 582.900 yuan and 2 000.000 yuan, respectively. The health utility value and VAS score of patients were lower in the early follow-up period, and gradually recovered in the later period. Conclusion The economic burden of HZ disease in rural areas of Jiangsu province was heavy, and the disease reduced the health-related quality of life of patients. -
Key words:
- Herpes zoster /
- Economic burden /
- Health-related quality of life
-
表 1 310名HZ患者的疾病经济负担[M(P25，P75)]
Table 1. Economic burden of disease in 310 patients with herpes zoster [M(P25, P75)]
变量 例数[n(%)] 直接经济负担(元) 间接经济负担(元) 无形经济负担(元) 性别 男 145(46.774) 388.500(183.750，644.900) 816.060(221.400，1 290.000) 2 000.000(1 000.000, 3 000.000) 女 165(53.226) 335.000(166.250, 556.125) 420.000(196.800, 728.625) 2 000.000(1 000.000, 2 000.000) Z值 -1.492 -2.357 -1.698 P值 0.136 0.018 0.089 就诊类型 门诊 298(96.129) 335.500(170.000, 579.250) 480.000(196.800, 924.480) 2 000.000(1 000.000, 3 000.000) 住院 12(3.871) 5 145.300(1 451.888, 6 525.000) 1 590.000(732.600, 2 169.908) 1 500.000(1 000.000, 8 250.000) Z值 -4.591 -2.540 -0.973 P值 ＜0.001 0.011 0.331 年龄(岁) 40~ < 50 31(10.000) 231.300(130.000, 440.000) 582.900(172.200, 1 032.900) 2 000.000(1 000.000, 3 000.000) 50~ < 60 82(26.452) 327.750(139.650, 558.750) 600.000(316.955, 845.205) 2 000.000(1 000.000, 3 000.000) ≥60 197(63.548) 378.000(200.935, 655.000) 531.450(196.800, 1 151.228) 2 000.000(1 000.000, 3 000.000) χ2值 7.266 0.026 4.225 P值 0.026 0.987 0.121 合计 310(100.000) 351.050(173.250, 602.500) 582.900(196.800, 1 020.075) 2 000.000(1 000.000, 3 000.000) 
下载: 导出CSV
表 2 310名带状疱疹患者的健康相关生命质量情况(按年龄组分层)
Table 2. Health-related quality of life in 310 patients with herpes zoster (stratified by age group)
变量与分组 例数[n(%)] 访视点 第1次(0 d) 第2次(15 d) 第3次(30 d) 第4次(60 d) 第5次(90 d) EQ-5D效用值(x±s) 40~ < 50岁 31(10.000) 0.706±0.266 0.860±0.165 0.923±0.144 0.967±0.082 0.973±0.105 50~ < 60岁 82(26.452) 0.715±0.213 0.871±0.156 0.959±0.081 0.996±0.021 0.998±0.011 ≥60岁 197(63.548) 0.650±0.260 0.823±0.195 0.933±0.111 0.988±0.042 0.996±0.024 合计 310(100.000) 0.673±0.250 0.840±0.184 0.939±0.108 0.988±0.045 0.994±0.039 EQ-VAS评分(x±s) 40~ < 50岁 31(10.000) 70.000±15.811 86.774±9.794 91.290±13.414 97.258±6.033 97.419±7.624 50~ < 60岁 82(26.452) 65.000±15.694 81.835±13.779 91.835±10.196 96.456±6.512 98.608±2.880 ≥60岁 197(63.548) 62.817±18.310 79.253±15.874 89.162±11.448 95.381±6.942 98.249±3.990 合计 310(100.000) 64.113±17.500 80.719±14.926 90.113±11.338 95.871±6.735 98.274±4.239 注：经重复测量方差分析，不同访视点EQ-5D效用值差异有统计学意义(F=361.604, P＜0.001)，EQ-VAS评分差异有统计学意义(F=571.042, P＜0.001)。
下载: 导出CSV
-
[1] Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(3): 103-108. DOI: 10.15585/mmwr.mm6703a5. [2] Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster[J]. J Clin Virol, 2010, 48: s2-s7. DOI: 10.1016/s1386-6532(10)70002-0. [3] Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life[J]. BMC Med, 2010, 8(1): 37. DOI: 10.1186/1741-7015-8-37. [4] Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults[J]. Clin J Pain, 2007, 23(6): 490-496. DOI: 10.1097/ajp.0b013e318065b6c9. [5] Luo N, Liu G, Li M, et al. Estimating an EQ-5D-5L value set for China[J]. Value Health, 2017, 20(4): 662-669. DOI: 10.1016/j.jval.2016.11.016. [6] 邢亚彬, 马爱霞. EQ-5D-5L中文版应用介绍[J]. 现代商贸工业, 2013, 25(1): 177-179. DOI: 10.19311/j.cnki.1672-3198.2013.01.099.Xing YB, Ma AX. EQ-5D-5L Chinese version application introduction[J]. Modern Business Trade Industry, 2013, 25(1): 177-179. DOI: 10.19311/j.cnki.1672-3198.2013.01.099. [7] 邓慧杰, 刘芳勋. 我国带状疱疹流行病学特征及疫苗免疫规划研究进展[J]. 中国继续医学教育, 2021, 13(19): 135-138. DOI: 10.3969/j.issn.1674-9308.2021.19.039.Deng HJ, Liu FX. Research progress of herpes zoster epidemiology and vaccine immunization program in China[J]. Chin Cont Med Edu, 2021, 13(19): 135-138. DOI: 10.3969/j.issn.1674-9308.2021.19.039. [8] Mizukami A, Sato K, Adachi K, et al. Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in Japanese adults aged 60 years or older: results from a prospective, observational cohort study[J]. Clin Drug Investig, 2018, 38(1): 29-37. DOI: 10.1007/s40261-017-0581-5. [9] Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective[J]. BMJ Open, 2014, 4(6): e4833. DOI: 10.1136/bmjopen-2014-004833. -
